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Cell penetrating peptides (CPPs), including arginine-rich peptides, are attractive tools 
for the intracellular delivery of various bioactive molecules with a low membrane 
permeability. We showed that the accelerated intracellular delivery of arginine-rich 
peptides was achieved by the addition of a short peptide segment (penetration 
accelerating sequence, Pas) to arginine-rich CPPs. The cytosolic release of the 
Pas-attached arginine-rich CPPs was observed within 5 min after the treatment of the 
cells with the peptides even in the presence of serum. Effectiveness of the Pas segment in 
the intracellular delivery of bioactive peptides using arginine-rich CPPs was exemplified 
through the enhanced growth inhibition activity of the malignant glioma cells by a 
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Arginine-rich cell penetrating peptides (CPPs), including the HIV-1 Tat peptide and 
oligoarginine peptides (Rn; n = 7~12), have been shown to deliver various bioactive 
molecules with a low membrane permeability into cells to regulate cell functions [1-4, 
and cited references]. This methodology has attracted our attention not only as a means 
of cell biological studies, but also because of its potential as therapeutic vectors. Efforts 
have continued for the development of novel CPPs with a high internalization efficiency, 
cell specificity, and low cytotoxicity. 
One of the important criteria for improving the internalization efficiency of 
arginine-rich peptides and their conjugates with cargoes should be the efficiency of the 
endosomal escape [5,6]. Involvement of endocytosis, including macropinocytosis, has 
been pointed out for the cellular uptake of arginine-rich CPPs and their conjugates [7-10 
and cited references]. Here the CPP conjugates are delivered into the cells by being 
trapped in the endosomes, and escape from the endosomal compartments is then 
necessary for functioning in the cytosol and nucleus. Approaches have been reported for 
the enhancement of the endosomal escape of the CPP conjugates. Disruption of the 
endosomes using pH-sensitive fusogenic peptides, such as the influenza hemagglutinin 
derived peptide HA2 [11] and artificially designed peptide GALA [12], is one approach. 
The treatment of cells with chloroquine and a photosensitizer may also improve the 
endosomal escape of the conjugates [13-16]. However, the former approaches employ 
peptides of more than 20 amino acid residues and the latter approaches may have rooms 
for further improvement for in vivo applications. Therefore, there remains room for 
developing more practical approaches.  
Cathepsin D is a lysosomal enzyme that can cleave peptide segments such as 
KPILFFRLK [17]. Considering the contribution of endocytosis to the cellular uptake of 
arginine-rich CPPs and their conjugates, involvement of this sequence in the CPP 
conjugates may lead to their partial decomposition in the endosomes/lysosomes that 
hamper their escape into the cytosol. During the course of our study using the partial 
segment (GKPILFF) of the above cathepsin D-cleavable sequence, a significant increase 
in the cellular uptake of octaarginine (R8) was observed by the attachment of this 
segment (R8-cathD, RRRRRRRR-GKPILFF) (Fig. 1A). Interestingly, the analogue 
called PasR8 (FFLIPKG-RRRRRRRR) having the retro sequence of R8-cathD was 
internalized into the cells much more efficiently than R8-cathD. Here, with the hope of 
enhancing the efficiency of the intracellular delivery by the addition of this FFLIPKG 
sequence to arginine-rich CPPs, we called the peptide segment FFLIPKG a penetration 
accelerating sequence (Pas). The hybrid peptide with R8 is thus referred to as PasR8 (Fig. 
1A).  
In this study, we report that the attachment of the Pas segment markedly enhanced the 
endosomal escape of the arginine-rich CPPs, and the growth of the malignant glioma 
cells was successfully inhibited by conjugation with the p53 C-terminal-derived peptide. 
 
2. Materials and Methods 
2.1 Synthesis 
All of the peptides used were chemically synthesized by Fmoc 
(9-fluorenylmethyloxycarbonyl) solid-phase peptide synthesis on a Rink amide resin as 
already reported [18]. Deprotection of the peptide and cleavage from the resin were 
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conducted by treatment with a trifluoroacetic acid/ethanedithiol mixture (95:5) at room 
temperature for 3 h followed by reversed-phase high performance liquid chromatography 
(HPLC) purification. Fluorescent labeling of the peptides was conducted by treatment 
with Alexa 488 C5 maleimide sodium salt (Invitrogen) in a dimethylformamide 
(DMF)/methanol mixture (1:1) for 1.5 h followed by HPLC purification. The structure of 
the products was confirmed by matrix-assisted laser desorption ionization time-of-flight 
mass spectrometry (MALDI-TOFMS).  
 
2.2 Cell culture 
The human cervical cancer-derived HeLa cells were maintained in -minimum 
essential medium with 10% heat-inactivated calf serum [-MEM(+)]. A subculture was 
performed every 3-4 days. The human malignant glioma cell lines A172 (expressing wild 
type p53), T98G (expressing the M237I mutant p53 [19]) and U251MG (expressing the 
R273H mutant p53 (homozygous) [19]) were provided by Health Science Research 
Resources Bank (Osaka, Japan), and were maintained in Dulbecco's Modified Eagle’s 
Medium [DMEM(+)] with 10% fetal bovine serum, 100 U/mL penicillin and 100 g/mL 
streptomycin. All cell lines were grown on 100-mm dishes and incubated at 37 °C under 
5% CO2 to approximately 70% confluence. 
 
2.3 Flow cytometry (FACS) 
HeLa cells (7.0 × 10
4
) in fresh culture medium were plated into 24-well microplates 
(Iwaki) and cultured for 48 h in -MEM(+). After complete adhesion, the cells were 
incubated at 37 °C with fresh medium containing fluorescently labeled peptides. After 
repetitive washing with PBS, the cells were treated with trypsin to ensure the removal of 
cell-surface-adsorbed peptides [8]. The cells were then washed with PBS and subjected 
to fluorescence analysis on a FACScalibur (BD Biosciences) flow cytometer using 
488-nm laser excitation and a 515- to 545-nm emission filter. For examination of the 
effect of cytochalasin D (CytD) on the cellular uptake of the peptides, the cells were 
preincubated with CytD (5 M) in -MEM(+) at 37 °C for 15 min. The cells were then 
treated with the peptide in the presence of 5 M CytD and analyzed by FACS. For 4 °C 
experiments, cells were preincubated in -MEM(+) at 4 °C for 1 h. The cells were 
washed, incubated in -MEM(+) containing peptides at 4 °C and analyzed by FACS.  
 
2.4 Confocal microscopy 
HeLa cells (2 × 10
5
) were plated on 35-mm glass-bottomed dishes (Iwaki) and 
cultured in -MEM(+) for 48 h. After complete adhesion, the culture medium was 
exchanged, and the cells were then incubated at 37 °C with fresh medium containing the 
fluorescently labeled peptides. After the incubation period, the cells were washed with 
PBS, and fresh culture medium was added. Distribution of the fluorescently labeled 
peptides was then analyzed using a confocal laser scanning microscope (CLSM) FV300 
(Olympus) equipped with a 40× objective without fixing the cells to avoid artifactual 
localization of the internalized peptides [8,20]. For examination of the effects of CytD on 
the cellular uptake of the peptides, the cells were preincubated with CytD (5 M) in 
-MEM(+) at 37 °C for 15 min. The cells were then treated with the peptide in 
-MEM(+) in the presence of 5 M CytD and analyzed by CLSM. For the 4 °C 
experiments, the cells were preincubated at 4 °C for 1 h. After the pretreatment period, 
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the cells were washed, incubated in -MEM(+) containing peptides at 4 °C and analyzed 
by CLSM. 
 
2.5 Cell viability assay 
A172, T98G and U251MG glioma cells (1.0 × 10
3
) were suspended in fresh 
DMEM(+) containing peptides (100 L) and each plated into 96-well microplates 
(Iwaki). Cell viability at each time point (4, 24, 48, 72 and 96 h) was determined using 
the WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene 
disulfonate) assay, according to the manufacturer’s protocol (Roche Applied Science) as 
already reported [11]. The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H- 
tetrazolium bromide] assay was conducted as already reported [21]. 
 
3. Results 
3.1 Rapid cellular uptake and cytosolic distribution of octaarginine peptides bearing the 
penetration accelerating sequence (Pas) segment 
The R8-cathD peptide has a hybrid sequence of the octaarginine (R8) CPP with the 
GKPILFF segment derived from a cathepsin D-cleavable sequence [17]. The PasR8 
peptide has the retro sequence of R8-cathD (Fig. 1A). The result of the analysis of the 
internalization efficiency of these peptides analyzed by FACS is given in Fig. 1B in 
which the HeLa cells were treated with these peptide (10 M each) for 30 min at 37 °C 























The amount of cellular uptake of R8-cathD was 5 times that of R8 (Fig. 1B). More 
surprisingly, that of PasR8 was about 18 times that of R8. Therefore, attachment of the 
Pas sequence (FFLIPKG) to R8 significantly enhanced the internalization. In addition, 
 
Fig. 1 
A) Structures of fluorescently labeled 
peptides used in this study in which an 
extension sequence of the Gly-Cys-amide 
was employed for the Alexa labeling. The 
dashed underline represents the Pas 
segment. B) Cellular uptake of PasR8 
analyzed by FACS. Cell line, HeLa; 
peptides, 10 M; incubation, for 30 min 
at 37 °C in -MEM(+). Means ± standard 
deviation (s.d.) of three experiments are 
shown. 
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the cellular uptake of PasR4 (FFLIPKG-RRRR) that lacks four arginine residues from 
PasR8 was slightly less than that of R8 (data not shown). This suggests that there may be 
a synergetic effect by using both the Pas and R8 segment for the uptake enhancement.  
A time course study of the cellular uptake of PasR8 showed a steep increase in the 
first 30 min to attain a plateau within 60 min under the given conditions (Fig. 2A). On 
the other hand, the amount of cellular uptake of R8 kept increasing during the 
observation period without reaching a plateau. The amount of PasR8 taken up by the 
cells in 30 min was more than 10 times that of R8. This result suggested the significant 
contribution of the Pas segment to accelerate the cellular uptake of R8. As shown in Fig. 
2B, diffuse signals of PasR8 into the cytosol and nucleus were observed by a confocal 
microscopic analysis in the first 5 min after the peptide treatment of the cells, whereas 
very few fluorescence signals were observed for R8 (Fig. 2B). A prolonged incubation 
for 180 min with PasR8 yielded the peptide signals colocalizing with the lysosome 
marker, Lysotracker. However, diffuse signals of PasR8 were predominantly observed in 
cytosol and nucleus (Supplementary data Fig. S1). In contrast, the R8 peptide only gave 
endosome-like punctate signals (Fig. S1), suggesting the facilitated endosomal escape by 
the addition of the Pas segment, and this would be favorable for delivering cargoes to 
influence the cellular activity and functions. In addition, there was no significant 






























A) Time course of cellular uptake of 
PasR8 (closed diamond) and R8 (open 
square). Cell line, HeLa; peptides, 10 
M; incubation, 15, 30, 60, and 180 
min at 37 °C in -MEM(+). The 
experiments were performed in 
triplicate. Error bars show the s.d. B) 
Rapid intracellular diffusion of PasR8. 
Cell line, HeLa; peptides, 10 M; 
incubation, 5 min at 37 °C in 
-MEM(+). Cells were washed three 
times with PBS after incubation and 
then observed by CLSM without 
fixation. Scale bars, 50 m. 
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lack of nuclear staining with a membrane impermeable dye, propidium iodide also 
assured the integrity of the plasma membranes [22] (data not shown). Importantly, this 
diffusion of PasR8 is observed in serum-containing medium, typically at the peptide 
concentration >5 M (Supplementary data Fig. S2). We previously reported that the 
serum-binding of the oligoarginine peptides results in a considerable decrease in the 
effective concentration of the peptides in the cultured media and this may hamper the 
cytosolic diffusion of the peptides [22]. The addition of the Pas sequence to R8 should be 
promising for obtaining a higher biological activity in cells.  
 
3.2 Energy-dependent intracellular diffusion of PasR8 
The contribution of endocytosis including macropinocytosis has been pointed out for 
the internalization of oligoarginine peptide. On the other hand, the possibility of the 
energy-independent direct penetration of oligoarginine to yield a diffuse cytosolic 
distribution of the peptides has been suggested when the concentration of the peptides 
exceeds a certain threshold [22]. Because PasR8 yielded significantly diffuse signals in 
the cytosol and nucleus within 5 min after the peptide treatment, the internalization 
methods of PasR8 were studied with R8 as a reference. HeLa cells were treated with 10 
M PasR8 and R8 at 37 and 4 °C in -MEM(+) for 15 min and analyzed by FACS (Fig. 
3A). There was an ~14-fold decrease in the amount of cellular uptake of PasR8 at 4 °C 
compared to that at 37 °C. Note that the amount of cellular uptake of PasR8 even at 4 °C 
was still comparable to that at 37 °C of R8 (Fig. 3A). The treatment of cells with 
cytochalasin D (CytD) prevents actin polymerization and the eventual macropinocytic 
uptake of R8 [8]. Similarly in the case of R8, the cellular uptake of PasR8 was inhibited 
to 60% by treatment with CytD (Fig. 3B). These results suggested that the cellular uptake 
of PasR8 employs energy-dependent pathways and macropinocytosis can be involved in 






















A) FACS analysis of the cellular uptake 
of PasR8 (black) and R8 (white) under a 
low temperature treatment. Cell line, 
HeLa; peptide, 10 M; incubation, 15 
min at 37 °C or 4 °C in -MEM(+). 
Means ± s.d. of three experiments are 
shown. B) Cellular uptake of PasR8 in the 
presence or absence of cytochalasin D 
(CytD) (5 M). Cell line, HeLa; peptide, 
10 M; incubation, 15 min at 37 °C in 
-MEM(+). Means ± s.d. of three 
experiments are shown. C) CLSM images 
of PasR8 (10 M) incubated with HeLa 
cells at 37 °C and 4 °C for 15 min in 
-MEM(+). Scale bars, 50 m.  
 8 
The CLSM analysis of cells treated with PasR8 at 4°C resulted in signals to a lesser 
extent than at 37 °C (Fig. 3C), suggesting that the cytosolic diffusion of PasR8 at 37°C is 
predominantly achieved during the early stage of the endocytic pathway, followed by 
leakage of the peptide through the endosomal membranes. On the other hand, diffuse 
signals of PasR8 were still observed in the cytosol and nucleus at 4 °C. This suggested 
the possible involvement of the energy-independent direct penetration pathways of 
PasR8 through the plasma membranes under the given conditions. Similar methods of 
cytosolic diffusion are also observed for cells treated with R8 at 4 °C [8,23]. 
 
3.3 Efficient internalization of flock house virus (FHV)-derived arginine-rich peptides 
bearing Pas 
To examine whether the addition of the Pas sequence to other arginine-rich peptides 
may also lead to the promotion of their cellular uptake, the flock house virus (FHV) coat 
protein-derived peptide [21] was employed as an example (Fig. 4A). The FHV peptide 
shows a higher internalization efficiency compared to the typical arginine-rich CPPs such 
as R8 and HIV-1 Tat peptides (the details will be reported elsewhere). We similarly 
attached the Pas segment to this peptide (PasFHV) (Fig. 4A) and evaluated the 
internalization efficiency into the cell. Almost an 8-fold increase in the cellular uptake 
was attained by the addition of the Pas segment to the FHV peptide (Fig. 4B). The CLSM 
analysis also showed an efficient distribution of PasFHV in the cytosolic and nucleic 
compartments (data not shown). A significant increase in the cellar uptake by the addition 
of the Pas segment was also observed for the Tat peptide (Supplementary data Fig. S3). 
These results suggested the generality of facilitating the cellular uptake of the 


























A) Structures of fluorescently-labeled 
PasFHV and FHV peptides bearing a 
Gly-Cys-amide segment for Alexa 
labeling. The Pas segment is highlighted 
by the dashed line. B) Enhanced cellular 
uptake by the attachment of the Pas 
segment to the FHV peptide. The HeLa 
cells were treated with a 10 M peptide 
for 15 min at 37 
o
C in -MEM(+); Means 
± s.d. of three experiments are shown. 
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3.4 Enhanced growth inhibition of malignant cells by intracellular delivery of a p53 
C-terminal-derived peptide using the FHV peptide with the Pas segment 
The effectiveness of the Pas addition to the intracellular delivery using arginine-rich 
peptides was evaluated through the delivery of a p53 C-terminal-derived peptide. A 
peptide segment derived from the p53 C-terminal 22 amino acid (361-382) has been 
reported to induce p53-dependent cell death in malignant cell lines [24,25]. The 
retro-inverso peptides that are composed of D-amino acids and have the sequences in the 
reverse order of the original peptides have side-chain spatial arrangements similar to 
those of the original peptides [26]. Because the D-amino acid segments are less 
susceptible to proteolytic degradation, the retro-inverso peptides are assumed to show a 
prolonged biological effect analogous to that of the original peptides. It has been reported 
that the retro-inverso version of the above p53-derived peptide (p53C') was successfully 
delivered into cells by conjugation with the Tat peptide and showed a sustained inhibition 
of cancer growth [27]. Using the flock house virus (FHV)-derived arginine-rich peptide, 
the effect of the Pas addition to this CPP was evaluated through the growth inhibition of 
malignant cells attained by the intracellularly delivered p53C' peptide using the WST-1 
assay.  
Three kinds of human malignant glioma cells expressing the wild type p53 protein 
(A172) and mutant p53 proteins (T98G and U251MG) were employed, and the growth 
inhibition of these cells by the treatment with peptides was examined for 96 h. The latter 
cell lines expressing the mutant p53 proteins have a diminished p53 activity, which often 
provides these cells with a resistance to anti-cancer reagents. Considering the prolonged 
incubation periods, the D-amino acid versions of the FHV (dFHV) and PasFHV 
(dPasFHV) peptides were employed as the delivery vectors, and their hybrid peptides 
with p53C' (dFHV-p53C' and dPasFHV-p53C', respectively) were synthesized (Fig. 5A). 
The effect of dPasFHV-p53C' on the cell growth of A172 cells was first evaluated using 
various concentrations (1-10 M) of the peptides at 4, 24, 48, 72 and 96 h (day 0-4), 
using the WST-1 assay. Significant suppression of the cell growth was observed at the 
peptide concentration of 5 M. Incubation of the cells with 10 M dPasFHV-p53C' 
resulted in complete suppression of the proliferation (Fig. 5B). Note that a single dose of 
peptides was applied to the cells only at time zero. The 10 M dPasFHV-p53C' yielded 
no significant proliferation not only of the wild-type, but also the mutant p53 expressing 
cells within 96 h (Fig. 5C). In contrast, only a slight suppression of proliferation was 
observed for the dFHV-p53C'-treated cells compared with the non-treated control cells. 
We also evaluated the conjugate of dPasFHV and mutant p53C' (dPasFHV-mp53C'); 
mp53C' has been reported to have a lower degree of cell growth suppression [27], and 
that attained by dPasFHV-mp53C' was not more spectacular than that by dPasFHV-p53C' 
(Fig. 5C). In addition, 10 M dPas-p53C' lacking the FHV segment 
(FFLIPKG-KKHRSTSQGKKSKLHSSHARSG-amide) yielded no significant cell growth 
inhibition (data not shown). Substitution of the dPasFHV segment to its L-isomer peptide 
also resulted in the almost complete loss of the suppression effect (Supplementary data 
Fig. S4). Employment of dPasR8 (D-amino acid versions of PasR8) instead of dPasFHV 
also yielded a reduced suppression effect (Supplementary data Fig. S4). Therefore, by 
conjugating the p53C' peptide with dPasFHV, a long-lasting suppression of malignant 
cell growth was attained. 
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Fig. 5 
A) Structures of dPasFHV-p53C' and 
dFHV-p53C'. The Pas segment is 
highlighted by the dashed line. The 
D-amino acids are shown in italics. A Gly 
residue was inserted as a linker to connect 
between the dPasFHV/dFHV and the 
p53C’ segments. B) Concentration 
dependence of dPasFHV-p53C' during 
the effect of the peptide treatment on 
proliferation of the human malignant 
glioma A172 cells. peptide, 1, 2, 5 and 10 
M; incubation, 4, 24, 48, 72 and 96 h 
(day 0-4) at 37 °C in DMEM(+). Means ± 
s.d. of three experiments are shown. C) 
Effect of the peptide treatment on 
proliferation of the human malignant 
glioma cells. Circle, dPasFHV-p53C'; 
triangle, dFHV-p53C'; cross, 
dPasFHV-mp53C' [mutant p53 C' 
peptides (mp53C') were designed by the 
substitution of three Lys with Glu or Ala, 
according to ref. 27)]; diamond, control. 
Cell line, A172 (upper panel), T98G 
(middle panel) and U251MG (lower 
panel); peptide, 10 M; incubation, 4, 24, 
48, 72 and 96 h (day 0-4) at 37 °C in 
DMEM(+). Means ± s.d. of three 
experiments are shown. 
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4. Discussion 
There is a growing interest in the utilization of CPPs as a vector for the intracellular 
delivery of bioactive molecules of low membrane permeability, and efforts are continuing 
to develop novel vectors of a high translocation efficiency. Endosomal escape of the 
CPPs into the cytosol is among the focuses of this challenge. A considerable portion of 
the CPPs is taken up by the cells using endocytosis including macropinocytosis and, in 
most cases, intracellularly delivered cargoes have to be delivered into the cytosol to exert 
their biological activity. In this study, we showed that the addition of a small peptide 
segment called a penetration accelerating sequence (Pas) significantly enhances the 
internalization efficiency of arginine-rich CPPs including the R8 and FHV peptides. 
Effective cytosolic diffusion of the PasR8 and PasFHV peptides was observed even in 
the presence of serum by CLSM observation. In addition, a significant decrease in the 
cellular uptake of PasR8 was observed at low temperature or during CytD treatment. 
These results suggest that PasR8 was predominantly taken up by the cells via endocytosis, 
followed by its efficient leakage from the endosomes into the cytosol. Considering that 
R8 without the Pas segment often yields punctate signals under the same conditions, a 
considerable amount of R8 is trapped in the endosomes. Therefore, the additional Pas 
segment may accelerate the translocation of PasCPPs through the endosomal membranes. 
In addition, a significant cytosolic diffusion of PasCPPs observed after only 5 min of 
peptide treatment of the cells strongly suggested that efficient leakage of the peptides 
from the endosomes was accomplished in the very early stages of their endocytic uptake. 
The detailed mechanism of this Pas-stimulated endosomal escape is currently under study 
in our laboratory. One possible explanation should be that the somewhat hydrophobic 
nature of the Pas segment (FFLIPKG) would increase the interaction of the peptides with 
the membranes to accelerate the release of the endosome-trapped peptides into the 
cytosol. However, considering that PasR8 and R8-cathD should have similar degree of 
hydrophobicity, there may be some factors other than hydrophobicity to explain the 
superiority of PasR8 in the cellular uptake. 
The addition of the Pas segments led to effective cytosolic diffusion of the 
fluorescently labeled R8 and FHV peptides even in a serum-containing medium. 
Assuming that the fluorescent moiety is a model of small molecular weight compounds, 
an increase in the cytosolic activity of the delivered cargo is also expected. This was 
exemplified through the growth inhibition of human malignant glioma cells by the 
delivery of the proteolytic resistant retro-inverso segment of a p53 C-terminal segment 
(p53C'). Almost complete inhibition of the cell growth was observed by the single 
administration of dPasFHV-p53C' (10 M), whereas only a slight inhibition was 
achieved in the dFHV-p53C'-treated cells. Of course, there may be a certain cargo effect 
in the cellular localization and internalization efficiency even in the delivery using 
PasCPPs, as pointed out for the CPP-mediated delivery [28]. However, this approach of 
the Pas attachment may provide a new platform for the intracellular delivery using CPPs.  
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Fig. S1  z-Stack CLSM analysis of cytosolic diffusion of PasR8. HeLa cells were 
treated with 10 M PasR8 or R8 for 180 min at 37 °C in -MEM(+). Cells were washed 
three times with PBS after incubation, treated with Lysotracker (50 nM) (Invitrogen) for 
1 min at 37 °Cin-MEM(+) and then observed by CLSM without fixation. Each picture 










Fig. S2  Concentration-dependent cellular uptake of PasR8. A) HeLa cells were treated 
with PasR8 (0.5, 1, 2.5, 5 and 10 M) for 15 min at 37 °C in -MEM(+) prior to analysis 
by flow cytometory. Experiments were performed in triplicate. Error bars show the s.d. 
B) HeLa cells were treated with peptides (2.5 and 5 M) for 15 min at 37 °C in 
-MEM(+). Cells were then washed three times with PBS and subjected to CLSM 















Fig. S3  Comparison of the cellular uptake efficiency of PasTat and PasR8. HeLa cells 
were treated with each peptide (10 M) for 15 min at 37 °C in -MEM(+) prior to the 





Fig. S4  A) Structures of dPasR8-p53C', dR8-p53C' and PasFHV-p53C'. The Pas 
segment is highlighted by the dashed line. D-amino acids are shown in italics. A Gly 
residue was inserted as a linker for connection between the CPP moieties and the p53C' 
segments. B) Employment of D-amino acid versions of the CPP is important to attain 
prolonged inhibition of the human malignant glioma cell growth. Closed circle, 
dPasFHV-p53C'; open circle, PasFHV-p53C'; closed diamond, control. Peptide, 10 M. 
C) Superior anti-proliferation activity of dPasFHV-p53C' over dPasR8-p53C'. Closed 
circle, dPasFHV-p53C'; open triangle, dR8-p53C'; open square, dPasR8-p53C'; closed 
diamond, control. Peptide, 10 M. Incubation, 4, 24, 48, 72 and 96 h (day 0-4) at 37 °C 
in DMEM(+). Means ± s.d. of three experiments are shown.  
 
